USPTO 2015–2025 USPTO PatentsView Foreign Corporation

GlaxoSmithKline Intellectual Property (No. 4) Limited

USPTO PatentsView assignee record - 87 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Glaxosmithkline ranks #4,118 of 49,997 tracked US assignees by granted-patent volume, with 87 patents across 16 technology areas.

#4,118
of 49,997 US assignees by volume
Top 32%
by Innovation Score (41.7/100)
15.7
avg claims per patent
-26%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4118 · Foreign Corporation #4,118 · 87 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 87 grants
  • TOP-DECILE #4,118/49,997
  • PHOTO-FINISH Daramic
  • CPC-FOCUS A61P · 16 areas
  • INNOV-PAR 41.7/100
  • CLAIMS-RICH 15.7 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -26% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Daramic, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Glaxosmithkline

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Glaxosmithkline's Innovation Score is 41.7/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Glaxosmithkline's grants concentrate

GlaxoSmithKline Intellectual Property (No. 4) Limited is a focused PatentsView assignee: 16 CPC subclasses with 95.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (13 grants) versus a trough of 1 in 2023. By volume, Glaxosmithkline sits between Daramic, LLC and Luxshare Precision Industry Company Limited.

Glaxosmithkline's three-year grant acceleration

From 2019–2021 to 2022–2024, GlaxoSmithKline Intellectual Property (No. 4) Limited moved from 32 to 13 grants (0.41x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Who files at GlaxoSmithKline's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows GlaxoSmithKline holds 87 patents at rank #4,118, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near GlaxoSmithKline

By rank, the assignees closest to #4,118 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in GlaxoSmithKline's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for GlaxoSmithKline, neither rank-band nor same-CPC leaders (those blocks stay above).

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 20152016201720182019202020212022202320242025 7
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
GlaxoSmithKline Intellectual Property (No. 4) Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 8 9.2%
2016 7 8.0%
2017 13 14.9%
2018 7 8.0%
2019 11 12.6%
2020 13 14.9%
2021 8 9.2%
2022 11 12.6%
2023 1 1.1%
2024 1 1.1%
2025partial year 7 8.0%

Where it ranks

Overall rank by patents

#4,118

of 49,997 tracked assignees

Innovation Score

41.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

GlaxoSmithKline Intellectual Property (No. 4) Limited's patent record in context - here's where to go next.

  • GlaxoSmithKline Intellectual Property (No. 4) Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 95.4% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #4,118 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare GlaxoSmithKline Intellectual Property (No. 4) Limited against Daramic, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 41.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.